# Interline Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/interline-therapeutics

- Industry: Pharmaceuticals
- Headquarters: South San Francisco, US
- Website: www.interlinetx.com
- Total disclosed funding: $83M
- Latest round: Series A (May 13, 2021)
- Investors on record: 2

## About

Based in California, US, and founded in 2020 by Zach Sweeney, a scientist with a track record of growing and leading successful drug discovery groups. Interline Therapeutics, Inc. operates as a pharmaceutical company focused on the research and development of therapeutic drugs for the prevention or treatment of human diseases. In May 2021, the company received Series A funding led by Foresite Capital and ARCH Venture Partners.

Interline Therapeutics uses genomics, proteomics, structural biology, and computational chemistry to systematically map and modulate protein communities. This will allow the company to identify new medicines targeting genetically validated signaling pathways and ensure that drug candidates comprehensively correct dysfunctional disease networks.

Interline Therapeutics intends to use the funds to double its team, expand its platform and drive six programs through preclinical development.

## Funding rounds

- Series A, May 13, 2021, $50M — ARCH Venture Partners, Foresite Capital
- Series A, Mar 4, 2021, $33M — ARCH Venture Partners, Foresite Capital

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series A